Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma

Perego, R; Corizzato, Matteo; Brambilla, Paola; Ferrero, Stefano; Bianchi, Cristina; Fasoli, Ester; Signorini, Stefano; Torsello, B; Invernizzi, L; Bombelli, S; Angeloni, Valentina; Pitto, Marina; Battaglia, Cristina; Proserpio, Vanessa; Magni, Fulvio; Galasso, Giacomo; Mocarelli, Paolo

doi:10.1016/j.ejca.2008.03.008

Cited by 31 publications

(41 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After a potential short term increase immediately after the surgical intervention due to DNA release from operatively damaged normal and tumor tissue, the decline depends on both the biological marker half-life and residual tumor cells. Correlations of decreasing cfDNA levels and successfully performed tumor resections were reported for lung [33], breast [34], colon [31,35], esophageal [36] and renal cancer [37]. In contrast, incomplete tumor resection or primary systemic tumor dissemination was assumed in patients with persistently increasing cfDNA values [31,36].…”

Section: Cfdnamentioning

confidence: 92%

CNAPS in Therapy Monitoring

Holdenrieder

2014

Advances in Predictive, Preventive and Personalised Medicine

View full text Add to dashboard Cite

Monitoring of disease state and of therapy response is highly relevant for efficient patient management. Monitoring tools comprise observation of clinical signs and performing specific examinations such as imaging or blood analyses. This review focusses on the relevance of blood-based biomarker monitoring by circulating nucleic acids for diverse indications that is exemplified on patients who develop or suffer from cancer disease. These indications include (i) screening of patient groups who have a risk to develop a disease, (ii) monitoring response to local or systemic therapies in patients with a defined diagnosis and (iii) early detection of disease recurrence after the primary therapy has ended. Useful biomarkers have to fulfill the highest methodical, pre-analytical and clinical quality criteria and have to be implemented in standardized patient management procedures. The current situation of circulating nucleic acids is summarized on the levels of genetic, epigenetic, transcript, non-coding RNA and nucleosome markers and an outlook is presented as to how these markers can be integrated into a future strategy that enables a personalized management of the patients.

show abstract

Section: Cfdnamentioning

confidence: 92%

CNAPS in Therapy Monitoring

Holdenrieder

2014

Advances in Predictive, Preventive and Personalised Medicine

View full text Add to dashboard Cite

show abstract

“…Whether an increased amount of plasma cfDNA might be useful for an early detection of disease recurrence in NSCLC patients [30] has to be seen in future trials. In contrast, there was no association between post-surgery cfDNA levels and disease recurrence in patients with renal-cell carcinoma [31]. A group of 15 patients suffering from a variety of different malignancies (all solid tumors) who were treated with radiation therapy were followed over several months and their plasma cfDNA was quantified [32].…”

Section: Dna Quantification/dna Integritymentioning

confidence: 96%

Extracellular Nucleic Acids and Cancer

Fleischhacker¹,

Schmidt²

2014

Advances in Predictive, Preventive and Personalised Medicine

View full text Add to dashboard Cite

Since the clear proof of the presence of tumor-associated genetic alterations in extracellular nucleic acids almost 20 years ago this field gained has attracted much interest. According to our current knowledge it seems as if all tumor-associated alterations found in tumor cells are also found in the extracellular environment. The isolation of extracellular nucleic acids from tumor patients and its genetic characterization with very sensitive and highly specific methods led to the concept of "liquid biopsy". This means that for follow-up analysis of tumor patients, the physicians no longer depend exclusively on a single examination of tissue biopsies (usually at the time of diagnosis) but are able by longitudinally analyzing the extracellular nucleic acids to follow the reaction of a tumor to e.g. a given therapy, the development of resistance mechanisms. In this chapter we will discuss the detection and characterization of different genetic (e.g. mutation analysis and structural variations as seen in microsatellites), epigenetic (e.g. hypermethylation of selected sequences) and regulatory alterations (as in different miRNA expression patterns found in tumor patients). We will also touch on some confounding factors that have to be taken into consideration as well as the functional and biological aspects of extracellular nucleic acids.

show abstract

“…На сегодняшний день много работ посвящено изучению микросателлитных перестроек в цирДНК крови [107][108][109][110][111][112][113]. Микросателлиты -короткие повторяющиеся и высокополиморфные последовательности, состоящие из многократно повторяющегося мотива, например, ди-, три-, тетрануклеотида: (NN-N)n. Микросателлиты более или менее случайно распределены в геноме [114].…”

Section: особенности строения внеклеточных днк кровиunclassified

“…Биологическая функция микросателлитов неясна, однако они часто используются в качестве генетических маркеров для анализа расположения генов-супрессоров опухолей и т.д. Опухолеассоциированные нарушения микросателлитной ДНК были обнаружены в цирДНК плазмы крови при раке лёгких [107], головы и шеи [108], почки [109], мочевого пузыря [110], предстательной железы [111,112] и гепатоцеллюлярной карциноме [113].…”

Section: особенности строения внеклеточных днк кровиunclassified

Generation of blood circulating DNA: the sources, peculiarities of circulation and structure

Bryzgunova

Laktionov

2015

BIOMED KHIM

View full text Add to dashboard Cite

Внеклеточные нуклеиновые кислоты (внНК) в циркуляции как здоровых, так и больных людей были впервые описаны в 1948 г., однако оставались без внимания до середины 60-х годов прошлого века. внНК особенно интенсивно исследуются в последние 5 лет. Основное внимание уделяется исследованию внНК как источнику диагностического материала; однако механизмы генерации внеклеточных нуклеиновых кислот, а также механизмы, обеспечивающие их долговременную циркуляцию в кровотоке, однозначно не установлены. По данным одних авторов, основным источником циркулирующих дезоксирибонуклеиновых кислот в крови (цирДНК) являются процессы некроза и апоптоза, другие ссылаются на возможную секрецию нуклеиновых кислот как здоровыми, так и опухолевыми клетками. Известно, что цирДНК могут циркулировать в крови в течение длительного времени, ускользая от действия ДНК-гидролизующих ферментов крови и, по-видимому, находясь в составе надмолекулярных комплексов. В этом обзоре представлены данные разных авторов и приведены доказательства в пользу всех предложенных теорий появления цирДНК, описаны особенности строения цирДНК, а также факторы, влияющие на время циркуляции ДНК в крови.Ключевые слова: циркулирующая ДНК, апоптоз, некроз, активная секреция, ДНКазы, метилирование.

show abstract

Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma

Cited by 31 publications

References 21 publications

CNAPS in Therapy Monitoring

CNAPS in Therapy Monitoring

Extracellular Nucleic Acids and Cancer

Generation of blood circulating DNA: the sources, peculiarities of circulation and structure

Contact Info

Product

Resources

About